Business
Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
- Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a
About this update from Aclaris Therapeutics, Inc.
[{"type":"text","content":"- Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of bosakitug (ATI-045) in patients with moderate-to-severe atopic dermatitis (AD). Top line results are expected in the fourth quarter of 2026. “The strong interest in participating in this Phase 2 trial reflects the urgent need for innovative solutions in atopic dermatitis and the excitement surrounding bosakitug and the potential role of TSLP as a therapeutic target in this setting,” said Dr. Jesse Hall, Chief Medical Officer of Aclaris. “Given the compound’s potential best-in-class potency and long natural half-life of 23 days, bosakitug has the potential to maximize TSLP inhibition in the skin while providing convenient dosing. We are proud to achieve this important milestone, and grateful to the participating physicians and patients for choosing to join our trial.” This randomized, double-blind, placebo-controlled Phase 2 trial will evaluate the efficacy and safety of bosakitug in 109 patients with moderate-to-severe atopic dermatitis. The primary efficacy endpoint is percent change from baseline in Eczema Area and Severity Index (EASI) at week 24. Secondary endpoints at week 24 include EASI response (EASI-50, EASI-75, EASI-90), validated Investigator Global Assessment (IGA) response, body surface area (BSA) response, and Peak Pruritus Numerical Rating Scale (PP-NRS) score, relative to baseline. Safety, tolerability, pharmacodynamic (PD) biomarkers, and pharmacokinetic profile (PK) will also be assessed. About Bosakitug (ATI-045) Bosakitug is an investigational humanized anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. This mechanism prevents immune cells targeted by TSLP from releasing proinflammatory cytokines. Bosakitug has potential best-in-class properties, including a very high affinity to TSLP, very high potency, an extremely low dissociation rate from TSLP leading to long residence time and ...